Metsera reports positive Phase 1 data for obesity drug MET-233i: up to 8.4% weight loss at 5 weeks

Metsera, Inc.

SAD: mean placebo-subtracted weight loss 5.3% at day 8 for 2.4 mg; half-life ~19 days.
MAD: mean placebo-subtracted weight loss 8.4% at day 36 for 1.2 mg; all GI AEs mild.
MET-233i generally well-tolerated; most frequent AEs nausea/vomiting, dose-dependent.
Monotherapy trial (12 weekly doses) topline data expected late 2025; combo with MET-097i by year-end 2025/early 2026.
Also expect topline combo data for MET-034i + MET-097i in late 2025.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.